Chardan Capital Markets initiated coverage on Tourmaline with a new price target
$TRML
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Chardan Capital Markets initiated coverage of Tourmaline with a rating of Buy and set a new price target of $70.00